Alpha Tau Medical Ltd (DRTSW) News

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

- Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high...

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau to Participate in March Investor Conferences

JERUSALEM, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease

JERUSALEM, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

- High disease control rate and strong interim safety results observed in pancreatic cancer patients across...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]